BMAL1 and neoplasm: Unexpectedly though, Bmal1-deficient tumors responded to drug administration at ZT3 with a notably higher growth rate, perhaps because of a substantial induction of Hsp90 in the tumor (Fig. 5, G, I, and J); although not detected in steady-state protein expression (fig.